Purchase this article with an account.
Ximena Ortega, III, Hugo Quiroz-Mercado, Maria Ana Martinez-Castellanos; Prevalence And Course Of Strabismus In A Five-Year Follow Up For Infants Treated With Off Label Intravitreal Bevacizumab For Retinopathy Of Prematurity. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6380.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To present strabismus data in a five years follow up of premature infants treated with intavitreal bevacizumab (IB) for retinopathy of prematurity (ROP).
A prospective, logitudinal follow-up study was performed in 18 eyes of 13 premature patients treated with intravitreal bevacizumab for ROP. The eyes were divided into three groups: group I, eyes with stage 4a or 4b ROP that had no response to conventional treatment (n=4); group II, eyes with threshold ROP that were difficult to treat with conventional treatment (n=5); group III, eyes with high risk prethreshold or threshold ROP (n=9). Visual acuity indicators (including fixation behavior and presence or absence of nystagmus), ocular alignment and motility status, cycloplegic refraction, and structural outcomes were recorded.
The prevalence of strabismus at 5 years in our group was 16.6%, include abnormal fixation behavior, presence of amblyopia, previous vitrectomy surgery after tractional retinal detachment in two patients of group I, these two patients required surgery to correct the strabismus, an other patient has an accomodative esotropia that corrects with a +2.75D lens.
Our results shows that the higher prevalence of strabismus was present in patients who developed retinal detachment with a poor visual outcome. In this small series IB shows not to have a direct relationship in the development of ocular motility abnormalities.
Clinical Trial: :
This PDF is available to Subscribers Only